ACTU logo

ACTU Actuate Therapeutics Inc

NASDAQ Global Market · Biotechnology · Healthcare

$0.23
+0.01 (+5.38%)

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including…

Market Cap: $5.41Mactuatetherapeutics.com

Price

No data yet.

Social Signal Score

32
5d
20
1 mentions
—
30d
33
4 mentions
—
60d
33
4 mentions
—
90d
43
6 mentions
—
news: 6

Analyst Ratings

1 analyst
Buyconsensus
Strong Buy 0Buy 1Hold 0Sell 0Strong Sell 0
Avg price target$21+9220.9%
Low $21Median $21High $21
Current Consensus

Revenue

$0.00
$0.00
Mar 2023Sep 2026

Analyst Estimates

FY2025
$-1.08
$-1.13–$-1.02
3 analysts
FY2026
$-0.64
$-0.77–$-0.51
1 analysts
FY2027
$-0.39
$-0.58–$-0.19
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Daniel Schmitt
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
0.78
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-91.84
actuatetherapeutics.com